Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.

MLA

Hagiwara, Masayuki, et al. “Variant Isoforms of CD44 Involves Acquisition of Chemoresistance to Cisplatin and Has Potential as a Novel Indicator for Identifying a Cisplatin-Resistant Population in Urothelial Cancer.” BMC Cancer, vol. 18, Jan. 2018, p. 1–N.PAG. EBSCOhost, https://doi.org/10.1186/s12885-018-3988-3.

APA

Hagiwara, M., Kikuchi, E., Tanaka, N., Kosaka, T., Mikami, S., Saya, H., & Oya, M. (2018). Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer. BMC Cancer, 18, 1–N.PAG. https://doi.org/10.1186/s12885-018-3988-3

Chicago

Hagiwara, Masayuki, Eiji Kikuchi, Nobuyuki Tanaka, Takeo Kosaka, Shuji Mikami, Hideyuki Saya, and Mototsugu Oya. 2018. “Variant Isoforms of CD44 Involves Acquisition of Chemoresistance to Cisplatin and Has Potential as a Novel Indicator for Identifying a Cisplatin-Resistant Population in Urothelial Cancer.” BMC Cancer 18 (January): 1–N.PAG. doi:10.1186/s12885-018-3988-3.